Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles

Pharmaceutics

Satoko Kishimoto¹  Masayuki Ishihara¹  Megumi Takikawa²  Yasutaka Mori¹  Hidemi Hattori¹  Masanori Fujita¹ 

[1] Research Institute, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan;Department of Plastic Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513 Japan;

关键词: entrapment;    microparticles;    coating;    polymeric drug delivery systems;   

DOI  :  10.3390/pharmaceutics4010042

来源: mdpi

【 摘 要 】

Low-molecular-weight heparin/protamine microparticles (LMW-H/P MPs) were produced as a carrier for heparin-binding growth factors (GFs) and for various adhesive cells. A mixture of low-molecular-weight heparin (MW: approximately 5000 Da, 6.4 mg/mL) and protamine (MW: approximately 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles (0.5–3 µm in diameter). LMW-H/P MPs immobilize, control the release and protect the activity of GFs. LMW-H/P MPs can also bind to cell surfaces, causing these cells to interact with the LMW-H/P MPs, inducing cells/MPs-aggregate formation and substantially promoting cellular viability. Furthermore, LMW-H/P MPs can efficiently bind to tissue culture plates and retain the binding of important GFs, such as fibroblast growth factor (FGF)-2. The LMW-H/P MPs-coated matrix with various GFs or cytokines may provide novel biomaterials that can control cellular activity such as growth and differentiation. Thus, LMW-H/P MPs are an excellent carrier for GFs and various cells and are an efficient coating matrix for cell cultures.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.